A single executive appointment rarely signals a geopolitical shift. Yet when Daiichi Sankyo announced on 24 February 2026 that Dr Yuki Kondo — former Merck Japan president and architect of Keytruda’s blockbuster regional ascent — would assume its oncology Chief Marketing Officer role, the announcement carried a weight far beyond the usual C-suite reshuffle. It arrived at precisely the moment China’s biopharma mergers and acquisitions activity exploded 40% year-on-year, Astellas sealed a landmark bispecific antibody alliance worth nearly $1 billion with US-based Vir Biotechnology, and Daiichi’s own antibody-drug conjugate franchise Enhertu crested $3 billion in global sales. Taken together, these developments do not merely reflect Asia’s growing influence in oncology — they announce its arrival as the industry’s new centre of gravity.
Daiichi Sankyo’s Masterstroke — The Man Tasked With Defending Enhertu’s Empire
Dr Yuki Kondo’s appointment is a calculated act of competitive aggression. His tenure at Merck encompassed the Japan launch of Keytruda — now the world’s best-selling cancer medicine — alongside overseeing the COVID-19 vaccine rollout, an experience that sharpened his command of Japan’s notoriously demanding PMDA regulatory environment and his fluency with the key opinion leader networks that determine formulary inclusion across the Asia-Pacific region. He inherits at Daiichi Sankyo an oncology portfolio in exceptional health. Enhertu has redefined the treatment of HER2-positive breast cancer and is actively expanding its label into gastric cancers and non-small-cell lung cancer — a trajectory that analysts expect to propel revenues towards $5 billion by 2026’s close. Yet the challenge Kondo faces is as formidable as the opportunity.
Enhertu’s patent protections extend only to 2034, and Chinese biosimilar manufacturers are already circling with versions priced significantly below originator levels. Multinationals operating in Asia now confront a binary choice: forge partnerships with Chinese innovators and leverage their manufacturing scale, or risk haemorrhaging market share to domestic champions such as Innovent Biologics and Akeso, whose ADC and bispecific pipelines are priced 60% below Western originators. Kondo’s mandate, in this context, is nothing less than transforming Daiichi Sankyo from a respected Japanese specialist into an Asia-Pacific oncology sovereign.
Astellas and Vir Biotechnology — The Bispecific Arms Race Reaches Asia
Announced in parallel with Kondo’s appointment, Astellas Pharma’s alliance with San Francisco-based Vir Biotechnology represents a strategic leap of comparable ambition. The terms — $400 million upfront against $530 million in development and commercial milestones — underscore the seriousness with which Astellas is pursuing biologics credibility. The collaboration targets solid tumour T-cell engager bispecific antibodies, a class of medicines that recruit the immune system’s own T-cells to destroy cancer cells and which have already produced significant clinical results in haematological malignancies. Vir’s bispecific platform is engineered for enhanced tumour penetration, offering pharmacokinetic advantages over first-generation competitors including Roche and Genentech’s glofitamab and Regeneron’s odronextamab.
For Astellas, whose revenues have historically been anchored in small molecules such as enzalutamide, the alliance purchases biologics expertise at Phase I pricing — acquiring clinic-ready assets without bearing the full cost of early-stage discovery. The China dimension of this partnership is anything but incidental. Bispecific antibody manufacturing hubs in Shanghai and Wuxi are actively seeking technology transfer agreements, mirroring the trajectory of CAR-T pioneer Gracell Biotechnologies before its $1.2 billion acquisition by AstraZeneca. Astellas has positioned the alliance as the linchpin of its oncology transformation by 2030, and the manufacturing infrastructure now maturing across China’s Yangtze River Delta provides the industrial backbone to make that ambition credible.
China’s Biopharma Gold Rush — And What It Means for Asia’s Oncology Future
The broader context in which Kondo’s appointment and the Astellas-Vir alliance sit is one of extraordinary upheaval. China’s biopharma mergers and acquisitions activity shattered records in 2025, surging 40% year-on-year as multinational pharmaceutical companies competed frantically for cell and gene therapy platforms, CDMO partnerships, and domestic distribution networks. AstraZeneca’s $1.2 billion acquisition of Gracell secured CAR-T supremacy, whilst Roche’s $2.7 billion purchase of Carmot Therapeutics bolstered its metabolic disease pipeline. Underpinning the dealmaking frenzy is a CDMO infrastructure that has matured with remarkable speed: WuXi STA, Asymchem, and Porton Pharma have tripled their process chemistry capacity, attracting technology transfers from Pfizer and GSK.
China’s National Medical Products Administration has simultaneously accelerated approvals to approximately 180 days — roughly half the FDA’s current timeline — providing a further incentive for global sponsors to prioritise Chinese development pathways. The commercial evidence is equally compelling: BeiGene’s Brukinsa generated $1.2 billion in China sales alone in 2024, demonstrating that domestic Chinese companies can achieve pricing power parity with multinationals on their own soil. For Daiichi Sankyo’s Kondo, for Astellas, and for every Western oncology executive watching Asia’s transformation, the message is unambiguous — the centre of gravity in global biopharma has moved east, and the companies that recognise this shift earliest will define the next decade of cancer medicine.